Medicine, Health & Food

Medicine, Health & Food

The Association Between Anaplastic Lymphoma Kinase (ALK) with Histological Grading and Molecular Subtypes in Invasive Breast Carcinoma

Pages: 7  ,  Volume: 42  ,  Issue: 1 , December   2019
Received: 17 Dec 2019  ,  Published: 23 December 2019
Views: 69  ,  Download: 28

Authors

# Author Name
1 Rini Flora Doloksaribu
2 Delyuzar
3 T. I. Alferraly

Abstract

Background: Breast carcinoma is the second most common cancer in the world and is the most common cancer among women. Research on protein expression is associated with prognosis and opportunities for providing therapeutic agents. Recent research examines ALK with various characteristics in breast cancer. Anaplastic Lymphoma Kinase (ALK) is a tyrosine kinase receptor that plays a role in the signal transduction pathway, including the ERK, JAK / STAT, and PI3K-PKB / Akt pathways, that will cause proliferation and survival of tumour cells.

Objective: To analized the immunohistochemical expressions of ALK association with histological grading and molecular subtypes in invasive breast carcinoma patients.

Material dan Methods: Formalin-fixed paraffin-embedded tissue blocks of 44 invasive breast carcinoma patients were immunohistochemically studied for ALK expressions. All clinicopathological characteristics were obtained through medical records and pathology archives.

Results: This study found that positive ALK expression in 40 cases (90.1%), while a negative ALK expression of 4 cases (9.1%). The mean age of patients with invasive breast carcinoma was 47.40 (± 10.57) years. Patients with positive ALK expression had an average age of 46.08 ± 10.64 years, and the highest tumor size was T3 (75%). All cases with negative ALK expression were invasive carcinoma NST. This study also found that there was no relationship of ALK expression with grading and molecular subtypes in invasive breast carcinoma.

Conclusions: These findings can be considered in using ALK as a determinant of prognosis and therapeutic agents. The use of other biological markers and validation by using larger samples and more even distribution is needed for the determination of a more precise prognosis in this study.

Keywords: invasive breast carcinoma, ALK, ALK inhibitor

Keywords

References

1. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, et al. Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology (2011) 47, R11–R23.

2. Hanna MG, Najfeld V, Irie HY, Tripodi J, Nayak A. Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification. SpringerPlus (2015) 4:439.

3. Nassif S, El-Zaatari ZM, Attieh M, Hijazi M, Fakhreddin N, Aridi T, et al. Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. Medicine (2019) 98:32.

4. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human Breast Cancer. Biochem Biophys Res Commun 2007;358:399–403.

5. Kim MH, Lee S, Koo JS, Jung KH, Park IH, Jeong J, et al. Anaplastic lymphoma kinase gene copy number gain in in?ammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication. PLoS One 2015; 10:e0120320.

6. Anti-ALK,CD246 Antibody. 2019. Wuhan Fine Biotech Co. Available from: https://www.fn-test.com/antibody/primary-antibody/anti-alkcd246-antibody-2

7. Staining Protocol [product data sheet]. Pleasanton, CA: Diagnostic Biosystem; 2015.

8. To K, Tong JHM, Yeung KSF, Lung RWM, Law PPY, Chau SL. Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. J Thorac Oncol. 2013;8: 883-891.

9. Ali SN, Qureshi A, Fahim A, Khoso MY. Expression of anaplastic lymphokinase and HER2/neu immunostaining in patients with breast carcinoma. Int J Res Med Sci. 2018 Nov;6(11):3472-3477.

10. Mehrjardi AZ, Vaghefi A. Expression of Anaplastic Lymphoma Kinase Protein in Human Breast Cancer. Iranian Journal of Pathology (2013) 8 (1), 27 – 35

11. Siraj AK, Beg S, Jehan Z, Prabhakaran S, Ahmed M, Hussain A, et al. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res 2015;17:127.

12. Goldhirsch, A, Wood WC, Coates AS, Gelber RD, Thürlimann, B, Senn HJ. (2011). Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22(8), 1736–1747.

13. Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. 2018Front. Oncol. 8:227.

14. Choi J, Jung W, Koo J. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. 2013. Pathobiology, 80, 41–52.

15. El-Hawary AK, Abbas AS, Elsayed AA, Elsayed AA, Zalata KR (). Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features. 2012. Pathol Res Pract, 208, 382–6.

16. Ambroise M, Ghosh M, Mallikarjuna V, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. 2011Asian Pacific J CancerPrev, 12, 625–9.

17. Elesawy BH, Abd A, Shawky AE, Arafa M. Immunohistochemistry-based subtyping of breast carcinomain Egyptian women: A clinicopathologic study on 125 patients. 2014. Ann Diagn Pathol, 18, 21–6.

18. Kadivar M, Mafi N, Joulaee A, Shamshiri A. Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011. Asian Pacific J Cancer Prev, 2012;13, 1881–6.

19. Siadati S, Sharbatdaram M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other prognostic factors in infiltrating ductal carcinoma of breast. Iran J Pathol, 2015;10, 221–6.

20. Tamaki M, Kamio T, Kameoka S, Kojimahara N, Nishikawa T. The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. World J Surg Oncol, 2013;11, 1–13.

21. Singh A, Singh A, Kishore K, Verma AK, Kant S. Crizotinib in treatment of lung cancer. Muller J Med Sci Res; 2017;8:65-7

22. Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R.Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.Transl Lung Cancer Res. 2014;3(2):70–4.

23. Cruz-Rico G, Avilés-Salas A, Segura-González M, Espinosa-García AM, Ramírez-Tirado LA, Morales-Oyarvide V, et al. Diagnosis of EML4-ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with non-small cell lung cancer. Am J Clin Oncol. 2015;11

24. Ding S, Liu N, Zhao H, Jiang G, Zhang X, Wang E. Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.2016. china: Tumor Biol.